ConductScience.org, home

Paper19854499

Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.

Maguire AM and 32 others. Lancet, 2009. Cited by 694 papers, by iCite.

Cite this record

ConductScience Library. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Papers, record 19854499. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19854499

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
PubMed
Journal
Lancet
PubMed
Year
2009
PubMed
Publication types
Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
694
iCite
Relative citation ratio, by iCite
16.9
iCite
Revised in PubMed
2026-01-28
PubMed

Authors33

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Maguire AMAlbert M
2High KAKatherine A
3Auricchio AAlberto
4Wright JFJ Fraser
5Pierce EAEric A
6Testa FFrancesco
7Mingozzi FFederico
8Bennicelli JLJeannette L
9Ying GSGui-shuang
10Rossi SSettimio
11Fulton AAnn
12Marshall KAKathleen A
13Banfi SSandro
14Chung DCDaniel C
15Morgan JIJessica I W
16Hauck BBernd
17Zelenaia OOlga
18Zhu XXiaosong
19Raffini LLeslie
20Coppieters FFrauke

Source PubMed

See all 33 authorsDownload CSV of authors

Topics27

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carrier ProteinsMajor topic
Eye ProteinsMajor topic
Genetic TherapyMajor topic
Optic Atrophy, Hereditary, LeberMajor topic
Adolescent
Adult
Age Factors
Blindness
Child
Dark Adaptation
Dependovirus
Disease Progression
Dose-Response Relationship, Drug
Electroretinography
Female
Genetic Vectors
Humans
Injections
Male
Mutation
Nystagmus, Physiologic
Safety
Treatment Outcome
Visual Acuity
Young Adult
cis-trans-Isomerases
Retinoid Isomerohydrolase

Source PubMed

Download CSV of topics

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Howard Hughes Medical InstituteUnited StatesPubMedPubMed
GGP07180TelethonItalyPubMedPubMed
U10 EY013729NEI NIH HHSUnited StatesU10EY013729PubMed and NIHNIH RePORTER
UL1-RR-024134NCRR NIH HHSUnited StatesUL1RR024134PubMed and NIHNIH RePORTER
R01 EY010820NEI NIH HHSUnited StatesR01EY010820PubMed and NIHNIH RePORTER
TGM06B01TelethonItalyPubMedPubMed
UL1 RR024134NCRR NIH HHSUnited StatesUL1RR024134PubMed and NIHNIH RePORTER
ZIAEY000260NIHNIH RePORTER

Download CSV of grants

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00516477Safety Study in Subjects With Leber Congenital AmaurosisResultsYesClinicalTrials.gov
NCT00999609Safety and Efficacy Study in Subjects With Leber Congenital AmaurosisBackgroundClinicalTrials.gov
NCT01208389Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2BackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in19854500Promises and challenges of genetic therapy for blindness.https://conductscience.org/library/papers/19854500

Source PubMed

Download CSV of comments and corrections

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115037595Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis.Invest Ophthalmol Vis Sci2004https://conductscience.org/library/papers/15037595PubMed
215957611Test-retest reliability of the multifocal electroretinogram and humphrey visual fields in patients with retinitis pigmentosa.Doc Ophthalmol2004https://conductscience.org/library/papers/15957611PubMed
319583479Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year.Hum Gene Ther2009https://conductscience.org/library/papers/19583479PubMed
418774912Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.Hum Gene Ther2008https://conductscience.org/library/papers/18774912PubMed
518809924Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.Proc Natl Acad Sci U S A2008https://conductscience.org/library/papers/18809924PubMed
616096063Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium.Cell2005https://conductscience.org/library/papers/16096063PubMed
719675341Vision 1 year after gene therapy for Leber's congenital amaurosis.N Engl J Med2009https://conductscience.org/library/papers/19675341PubMed
818441370Safety and efficacy of gene transfer for Leber's congenital amaurosis.N Engl J Med2008https://conductscience.org/library/papers/18441370PubMed
914759802In utero gene therapy rescues vision in a murine model of congenital blindness.Mol Ther2004https://conductscience.org/library/papers/14759802PubMed
1016226919Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.Mol Ther2005https://conductscience.org/library/papers/16226919PubMed
1110937591Early-onset severe rod-cone dystrophy in young children with RPE65 mutations.Invest Ophthalmol Vis Sci2000https://conductscience.org/library/papers/10937591PubMed
1216799026Eye movement recordings as an effectiveness indicator of gene therapy in RPE65-deficient canines: implications for the ocular motor system.Invest Ophthalmol Vis Sci2006https://conductscience.org/library/papers/16799026PubMed
1316150724Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle.Proc Natl Acad Sci U S A2005https://conductscience.org/library/papers/16150724PubMed
149843205Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle.Nat Genet1998https://conductscience.org/library/papers/9843205PubMed
1517724218Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients.Invest Ophthalmol Vis Sci2007https://conductscience.org/library/papers/17724218PubMed
1618209734Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer.Mol Ther2008https://conductscience.org/library/papers/18209734PubMed
1719953081Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.Mol Ther2010https://conductscience.org/library/papers/19953081PubMed
183976802Natural course of retinitis pigmentosa over a three-year interval.Am J Ophthalmol1985https://conductscience.org/library/papers/3976802PubMed
198382952Amplification and kinetics of the activation steps in phototransduction.Biochim Biophys Acta1993https://conductscience.org/library/papers/8382952PubMed
2012657591Latency of the pupil light reflex: sample rate, stimulus intensity, and variation in normal subjects.Invest Ophthalmol Vis Sci2003https://conductscience.org/library/papers/12657591PubMed

See all 25 referencesDownload CSV of references

Cited by464

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 694 citations.

PMIDTitleJournalYearIn PapersSource
42817933Host Endoplasmic Reticulum Stress and Interferon Responses Contribute to AAV-Induced Ocular Toxicity.bioRxiv2026https://conductscience.org/library/papers/42817933PubMed
42488178mRNA delivery to the retina restores REP1 function in choroideremia.Mol Ther Adv2026https://conductscience.org/library/papers/42488178PubMed
42242173Vein graft failure: Pathophysiology, detection, prevention and emerging therapeutic strategies.Pharmacol Rev2026https://conductscience.org/library/papers/42242173PubMed
42117798Voretigene Neparvovec Gene Therapy in Clinical Practice: A 12-Month, Single-Center, In-Depth Analysis of Beneficial and Adverse Drug Effects.Transl Vis Sci Technol2026https://conductscience.org/library/papers/42117798PubMed
42107518Modalities of vision restoration in optic neuropathies and retinal disease.Prog Retin Eye Res2026https://conductscience.org/library/papers/42107518PubMed
42083640Gene Therapy Using Recombinant Adeno-Associated Virus for Leber Congenital Amaurosis Induced by RPE65 Mutation.Clin Ophthalmol2026https://conductscience.org/library/papers/42083640PubMed
41751276Diagnostic Role of Chromatic Full-Field Stimulus Test in Rod-Cone Versus Cone Dystrophies.Biomedicines2026https://conductscience.org/library/papers/41751276PubMed
41618563Modification of the VP1u region boosts transduction of adeno-associated virus vectors for ocular gene therapy.Mol Ther2026https://conductscience.org/library/papers/41618563PubMed
41512965RNA-Based Therapies for Treating Monogenic Cardiomyopathies.Can J Cardiol2026https://conductscience.org/library/papers/41512965PubMed
41379738Chorioretinal Atrophy after Voretigene Neparvovec Therapy in <italic>RPE65</italic> Mutation-Associated Inherited Retinal Disease: Longitudinal Characterization in Multimodal Imaging.Ophthalmologica2026https://conductscience.org/library/papers/41379738PubMed
41254285Roadmap for direct and indirect translation of optogenetics into discoveries and therapies for humans.Nat Neurosci2025https://conductscience.org/library/papers/41254285PubMed
41223291Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2.Sci Adv2025https://conductscience.org/library/papers/41223291PubMed
41141388In vivo gene therapy: A strategy for mutations, degenerations, and tumors.Genes Dis2026https://conductscience.org/library/papers/41141388PubMed
41140124Clinical and pharmacovigilance safety evaluation of LUXTURNA® (voretigene neparvovec-rzyl).Cutan Ocul Toxicol2025https://conductscience.org/library/papers/41140124PubMed
41104263Characterization of adeno-associated viral transduction of retinal ganglion cells in adult and old mice.Mol Ther Methods Clin Dev2025https://conductscience.org/library/papers/41104263PubMed
40910102Efficacy and Safety of Voretigene Neparvovec in RPE65-Retinopathy: Results of a Phase III Trial in Japan.Ophthalmol Sci2025https://conductscience.org/library/papers/40910102PubMed
40725503Advances in Precision Therapeutics and Gene Therapy Applications for Retinal Diseases: Impact and Future Directions.Genes (Basel)2025https://conductscience.org/library/papers/40725503PubMed
40715346Regulation of RPE65 expression in human retinal pigment epithelium cells.Sci Rep2025https://conductscience.org/library/papers/40715346PubMed
40471435Gene therapy strategies in ophthalmology-an overview of current developments and future prospects.J Appl Genet2026https://conductscience.org/library/papers/40471435PubMed
40248125The clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysis.iScience2025https://conductscience.org/library/papers/40248125PubMed

See all 464 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
DCC1630PubTator's text mininghttps://conductscience.org/library/genes/1630NCBI Gene
IFI273429PubTator's text mininghttps://conductscience.org/library/genes/3429NCBI Gene
NDUFB1154539PubTator's text mininghttps://conductscience.org/library/genes/54539NCBI Gene
POTEF728378PubTator's text mininghttps://conductscience.org/library/genes/728378NCBI Gene
RDH12145226PubTator's text mininghttps://conductscience.org/library/genes/145226NCBI Gene
RPE656121PubTator's text mininghttps://conductscience.org/library/genes/6121NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
VORETIGENE NEPARVOVECCHEMBL3707275Results1https://conductscience.org/library/drugs/CHEMBL3707275

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19854499

GET https://conductscience.org/api/papers/v1/19854499/authors?page=2